These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36304121)

  • 21. An immunopotentiator, ophiopogonin D, encapsulated in a nanoemulsion as a robust adjuvant to improve vaccine efficacy.
    Tong YN; Yang LY; Yang Y; Song Z; Peng LS; Gao JN; Zeng H; Zou QM; Sun HW; Mao XH
    Acta Biomater; 2018 Sep; 77():255-267. PubMed ID: 30031164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting DNA vaccines to myeloid cells using a small peptide.
    Ye C; Choi JG; Abraham S; Shankar P; Manjunath N
    Eur J Immunol; 2015 Jan; 45(1):82-8. PubMed ID: 25270431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cell-targeted porcine reproductive and respiratory syndrome virus (PRRSV) antigens adjuvanted with polyinosinic-polycytidylic acid (poly (I:C)) induced non-protective immune responses against heterologous type 2 PRRSV challenge in pigs.
    Subramaniam S; Piñeyro P; Derscheid RJ; Madson DM; Magstadt DR; Meng XJ
    Vet Immunol Immunopathol; 2017 Aug; 190():18-25. PubMed ID: 28778318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CpG Oligodeoxinucleotides and Flagellin Modulate the Immune Response to Antigens Targeted to CD8α
    Antonialli R; Sulczewski FB; Amorim KNDS; Almeida BDS; Ferreira NS; Yamamoto MM; Soares IS; Ferreira LCS; Rosa DS; Boscardin SB
    Front Immunol; 2017; 8():1727. PubMed ID: 29255470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.
    Schmidt ST; Khadke S; Korsholm KS; Perrie Y; Rades T; Andersen P; Foged C; Christensen D
    J Control Release; 2016 Oct; 239():107-17. PubMed ID: 27574990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
    Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
    Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
    Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
    Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
    Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells.
    Matsuo H; Yoshimoto N; Iijima M; Niimi T; Jung J; Jeong SY; Choi EK; Sewaki T; Arakawa T; Kuroda S
    Int J Nanomedicine; 2012; 7():3341-50. PubMed ID: 22848163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice.
    Stylianou E; Pepponi I; van Dolleweerd CJ; Paul MJ; Ma JK; Reljic R
    Vaccine; 2011 Mar; 29(12):2279-86. PubMed ID: 21272603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity.
    Eko FO; Mania-Pramanik J; Pais R; Pan Q; Okenu DM; Johnson A; Ibegbu C; He C; He Q; Russell R; Black CM; Igietseme JU
    BMC Immunol; 2014 Dec; 15():584. PubMed ID: 25551828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
    Hesse C; Ginter W; Förg T; Mayer CT; Baru AM; Arnold-Schrauf C; Unger WW; Kalay H; van Kooyk Y; Berod L; Sparwasser T
    Eur J Immunol; 2013 Oct; 43(10):2543-53. PubMed ID: 23784881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy.
    Cruz LJ; Rueda F; Cordobilla B; Simón L; Hosta L; Albericio F; Domingo JC
    Mol Pharm; 2011 Feb; 8(1):104-16. PubMed ID: 21121669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting dendritic cells for improved HIV-1 vaccines.
    Smed-Sörensen A; Loré K
    Adv Exp Med Biol; 2013; 762():263-88. PubMed ID: 22975879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity.
    Schetters STT; Li RJE; Kruijssen LJW; Engels S; Ambrosini M; Garcia-Vallejo JJ; Kalay H; Unger WWJ; van Kooyk Y
    Biomaterials; 2020 Dec; 262():120342. PubMed ID: 32905903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-mimetic ligand selected by mRNA display targets DC-SIGN for dendritic cell-directed antigen delivery.
    Xiao L; Hung KC; Takahashi TT; Joo KI; Lim M; Roberts RW; Wang P
    ACS Chem Biol; 2013 May; 8(5):967-77. PubMed ID: 23427768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
    Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J
    J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycan-Modified Virus-like Particles Evoke T Helper Type 1-like Immune Responses.
    Alam MM; Jarvis CM; Hincapie R; McKay CS; Schimer J; Sanhueza CA; Xu K; Diehl RC; Finn MG; Kiessling LL
    ACS Nano; 2021 Jan; 15(1):309-321. PubMed ID: 32790346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
    Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
    J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.